On the fundamental side I loved these facts..
"revenue from Axiron of between US$7 million
and US$8 million in 2011/12 and approximately US$40 million in 2012/13. Acrux’s
operating expenditure is currently running at approximately $0.5 million per month"
$28Mil in the bank.
The first of the six potential net sales milestone payments is
expected to be received during the 2012/13 financial year.
"The board today reaffirmed its intention to declare the next dividend to shareholders
in August 2012"
I mean..wow what a great bio stock!
Add to My Watchlist
What is My Watchlist?
